Skip to main content
Clinical Trials/NCT04295213
NCT04295213UnknownNot Applicable

The Effect of a Oligosaccharides Versus a Placebo on Defecation Parameters in Healthy Children With Hard or Lumpy Stools

Wageningen University and Research2 sites in 1 country196 target enrollmentStarted: April 28, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
196
Locations
2
Primary Endpoint
Stool consistency

Study Overview

Brief Summary

In the present randomised double blind controlled study, we will study the effects of a oligosaccharides vs a placebo on the change in stool consistency and stool frequency in children with hard or lumpy stools.

Detailed Description

Firm, hard or lumpy stools can be problematic for young children and might come as a precursor of functional constipation in childhood. The cause of harder stools in childhood is incompletely understood. But it is likely that harder stools in childhood are linked to among others withholding behaviour of stools and a low fibre intake. As hard stools may precede functional constipation, the aim of the study is to investigate the effect of a prebiotic fiber versus a placebo on defecation parameters in healthy children with hard or lumpy stools. We hypothesize that consumption of a prebiotic fiber results in softer stools.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
1 Year to 3 Years (Child)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Written informed consent
  • aged 1-4 years
  • Hard and/or firm stools as scored by a stool questionnaire

Exclusion Criteria

  • Children that meet the Rome IV criteria for functional constipation
  • Children who suffer from any other GI complaints, known structural GI abnormalities, or previous GI surgery
  • Any condition that would make it unsafe for the child to participate.
  • Children with clinically significant cardiac, vascular, liver, pulmonary, psychiatric disorders, severe renal insufficiency, human immunodeficiency virus, acquired immunodeficiency syndrome, hepatitis B or C or known abnormalities of haematology, urinalysis, or blood biochemistry, as checked by the inclusion questionnaire.
  • Children who are allergic to cow's milk or fish
  • Use of antibiotics or other medicines or food supplements, and breast milkfeeding, which can influence defecation and gut microbiota 4 weeks prior to the study
  • Children that participate in another clinical trial

Outcomes

Primary Outcomes

Stool consistency

Time Frame: Stool consistency will be measured at different time points during a study period of 13 weeks.

Change in stool consistency measured by the a stool questionnaire; 5 points stool scale from 1 hard to 5 watery (modified Bristol Stool Form Scale)

Secondary Outcomes

  • Stool frequency in number of cases (%)(These outcome measures will be measured at different time point during a study period of 13 weeks.)
  • Stool consistency in number of cases (%)(These outcome measures will be measured at different time point during a study period of 13 weeks.)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Clara Belzer

Associate Professor

Wageningen University and Research

Study Sites (2)

Loading locations...

Similar Trials